MBRX

Moleculin Biotech, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-18

Figures on this page computed 2026-11-07 17:38 UTC

Last close

8.46USD

Market data, 2026-11-04

MBRX: weekly closes from 244.60 on 2025-11-07 to 8.46 on 2026-11-04, a move of -96.5%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: -96.5%

Except where said otherwise: 10-K for 2025, filed 2026-03-18

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
-387.0%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
0.02Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Returns on capital is the furthest below its sector's middle: 0.03 against 0.25 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

n/a

1.76x

1.29x

1.13x

0.00x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-18

Salesn/a
Its own average over 10 years, 0.
Profit1.76x
Its own average over 10 years, -19.0M.
Free cash flow1.29x
Its own average over 10 years, -17.6M.
Debt1.13x
Its own average over 9 years, 317.2K.
Price0.00x
Its own average over 6 years, 4.4K. Market data, 2026-11-04

Price is furthest from its own average, at 0.00 times.

The filed years, as a table

Each line is 100 at 2021-12-31, the first year we hold.

Filed year	Shares in issue
2021-12-31	100.0
2022-12-31	106.4
2023-12-31	110.3
2024-12-31	192.2
2025-12-31	1,652.8

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001437749-26-008841
Reported in: USD

The filing itself

Figures behind the shape

Growth

-28.8%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
One-year change in net income-28.8%
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Returns on capital

-387.0%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capital-387.0%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on equity-223.6%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on assets-151.7%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself

Margins

n/a

We do not hold this figure for this company, so there is nothing to place.

wider is higher, with no cohort held

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Operating marginn/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Net marginn/a
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Free cash flow marginn/a
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself

Price

0.03x

cheaper is higher, placed against 4,482 companies as of 2026-11-06

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
Price to book0.03x10-Q for 2025, filed 2026-08-13
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001437749-26-027688
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-13
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
The filing itself
Price to sales ration/a
We do not hold this figure for this company, so there is nothing to place.
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself

Safety

0.02

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equity0.02
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
Current ratio1.4110-Q for 2025, filed 2026-08-13
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001437749-26-027688
Reported in
USD
- 10-Q for 2025, filed 2026-08-13
- 10-Q for 2025, filed 2026-08-13
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Altman Z-Score-16.58
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-06
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.